Ruth Oâ€™Regan, MD

Articles by Ruth Oâ€™Regan, MD

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

ByElisavet Paplomata, MD,Ruth Oâ€™Regan, MD

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Latest Updated Articles

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer
March 27th 2015

Ruth Oâ€™Regan, MD

Articles by Ruth Oâ€™Regan, MD

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS

Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles

Dr Marvin-Peek on the Significance of Efficacy Data for Azacitidine/Ivosidenib/Venetoclax in IDH1-Mutated AML